NASDAQ:TELO Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis $1.14 -0.05 (-4.20%) As of 08/28/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Telomir Pharmaceuticals Stock (NASDAQ:TELO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TELO alerts:Sign Up Key Stats Today's Range$1.14▼$1.2050-Day Range$0.92▼$1.3052-Week Range$0.89▼$2.09Volume36,957 shsAverage Volume54,854 shsMarket Capitalization$78.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited. The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling. In parallel, Telomir maintains a preclinical pipeline of compounds designed to act on distinct molecular targets with the goal of delivering differentiated safety and efficacy profiles. Collaborative partnerships with academic institutions and contract research organizations support translational research efforts and accelerate compound progression from discovery through early clinical evaluation. Headquartered in the United States, Telomir Pharmaceuticals is guided by an executive team with extensive experience in biopharmaceutical research, clinical development and regulatory affairs. While the company’s initial focus is on advancing its lead programs through clinical milestones in North America, management has articulated plans to pursue strategic alliances that could enable broader international development and commercialization. As a Nasdaq-listed entity, Telomir continues to refine its pipeline and expand its scientific platform with the goal of delivering innovative therapies to patients around the world.AI Generated. May Contain Errors. Read More Telomir Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreTELO MarketRank™: Telomir Pharmaceuticals scored higher than 14% of companies evaluated by MarketBeat, and ranked 858th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingTelomir Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageTelomir Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Telomir Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Telomir Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Telomir Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTelomir Pharmaceuticals has a P/B Ratio of 16.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Telomir Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.41% of the float of Telomir Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTelomir Pharmaceuticals has a short interest ratio ("days to cover") of 16.25, which indicates bearish sentiment.Change versus previous monthShort interest in Telomir Pharmaceuticals has recently decreased by 15.52%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTelomir Pharmaceuticals does not currently pay a dividend.Dividend GrowthTelomir Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.63 News SentimentTelomir Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Telomir Pharmaceuticals this week, compared to 1 article on an average week.Search Interest3 people have searched for TELO on MarketBeat in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Telomir Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders16.36% of the stock of Telomir Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsTelomir Pharmaceuticals has minimal institutional ownership at this time.Read more about Telomir Pharmaceuticals' insider trading history. Receive TELO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telomir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TELO Stock News HeadlinesTelomir Pharmaceuticals (TELO) Expected to Announce Quarterly Earnings on WednesdayAugust 26, 2026 | americanbankingnews.comTelomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer ModelsAugust 10, 2026 | markets.businessinsider.com#1 Stock to Own as Trump Launches Historic Mission Backing "Medical AI"The federal government is throwing its full support behind a new class of AI technology, in what's being called the biggest push since the Apollo moon landing. This AI reportedly works 10,000 times faster than human PhDs and could eventually be worth 500 times more than ChatGPT. Elon Musk has called the underlying tech the most disruptive force in history.August 30 at 1:00 AM | Stansberry Research (Ad)Telomir-Zn Preclinical Data Support Advancement in TNBCAugust 10, 2026 | tipranks.comTelomir Pharmaceuticals Announces Peer-Reviewed Publication of Preclinical Telomir-Zn Data Showing Tumor Suppression in Prostate and Triple-Negative Breast Cancer ModelsAugust 10, 2026 | quiverquant.comQTELO Telomir Pharmaceuticals, Inc.July 8, 2026 | seekingalpha.comTelomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical ...June 15, 2026 | usatoday.comTelomir Showcases Preclinical Telomir-Zn Diabetes Efficacy DataJune 15, 2026 | tipranks.comSee More Headlines TELO Stock Analysis - Frequently Asked Questions How have TELO shares performed this year? Telomir Pharmaceuticals' stock was trading at $1.33 at the beginning of the year. Since then, TELO stock has decreased by 14.3% and is now trading at $1.14. How were Telomir Pharmaceuticals' earnings last quarter? Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) released its quarterly earnings data on Thursday, August, 13th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.72. When did Telomir Pharmaceuticals IPO? Telomir Pharmaceuticals (TELO) raised $7 million in an initial public offering (IPO) on Friday, February 9th 2024. The company issued 1,000,000 shares at a price of $7.00 per share. Kingswood Investments served as the underwriter for the IPO. Who are Telomir Pharmaceuticals' major shareholders? Telomir Pharmaceuticals' top institutional shareholders include BlackRock Inc. (0.41%), Bank of New York Mellon Corp (0.07%) and OneDigital Investment Advisors LLC (0.03%). How do I buy shares of Telomir Pharmaceuticals? Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today8/30/2026Next Earnings (Estimated)9/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 3 weeks, TELO's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TELO Previous SymbolNASDAQ:TELO CIK1971532 Webtelomirpharma.com Phone(737)-289-0835FaxN/AEmployees1Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-102.70% Return on Assets-90.75% Debt Debt-to-Equity RatioN/A Current Ratio16.16 Quick Ratio16.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book6.71Miscellaneous Outstanding Shares68,780,000Free Float57,523,000Market Cap$78.41 million OptionableN/A Beta-0.24 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:TELO) was last updated on 8/30/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhy Boston Ships In Natural Gas It Already Has at HomeA tanker called the Iberica Knutsen once sailed 2,272 miles from Trinidad and Tobago to deliver liquefied natu...Porter & Company | SponsoredSPDR Gold just lost $14 billion.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
